161 related articles for article (PubMed ID: 32544366)
1. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.
Pouwels XGLV; Ramaekers BLT; Geurts SME; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; van Riel JMGH; Pepels MJ; Heijnen-Mommers J; Tjan-Heijnen VCG; de Boer M; Joore MA
Acta Oncol; 2020 Sep; 59(9):1123-1130. PubMed ID: 32544366
[No Abstract] [Full Text] [Related]
2. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Lopes G; Glück S; Avancha K; Montero AJ
Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
[TBL] [Abstract][Full Text] [Related]
3. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
[TBL] [Abstract][Full Text] [Related]
4. The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.
Pouwels XGLV; Geurts SME; Ramaekers BLT; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; Riel JMV; Pepels MJ; Heijnen-Mommers J; Joore MA; Tjan-Heijnen VCG; de Boer M
Acta Oncol; 2020 Jan; 59(1):82-89. PubMed ID: 31583931
[No Abstract] [Full Text] [Related]
5. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
Loke L; Lee SC; Pearce F; Ng K; Aziz MIA
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1308. PubMed ID: 33085843
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
10. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
12. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.
Hurtaud A; Donnadieu A; Escalup L; Cottu PH; Baffert S
Breast; 2016 Dec; 30():73-79. PubMed ID: 27639032
[TBL] [Abstract][Full Text] [Related]
13. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
van Kampen RJW; Ramaekers BLT; Lobbezoo DJA; de Boer M; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FPJ; van Riel JMG; Peters NAJB; Tjan-Heijnen VCG; Joore MA
Eur J Cancer; 2017 Jul; 79():238-246. PubMed ID: 28245951
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.
Tremblay G; Majethia U; Breeze JL; Kontoudis I; Park J
Clinicoecon Outcomes Res; 2016; 8():485-493. PubMed ID: 27698565
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
[TBL] [Abstract][Full Text] [Related]
17. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
20. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
Liu Z; Doan QV; Malin J; Leonard R
Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]